🚨#qFibrosis shows 89.2% repeatability (κ=0.88) and 86.5% reproducibility (κ=0.85) in liver fibrosis scoring, matching human pathologist agreement. The AI platform addresses variability in MASH trials, enabling standardized histological assessment.

🔗:https://ow.ly/miua50YpGRV

HistoIndex's FibroSIGHT™ Plus: A Major Leap in Fibrosis Diagnosis Through AI Technology HistoIndex has launched FibroSIGHT™ Plus, an innovative tool that employs AI for quantitative fibrosis assessment, transforming diagnostic processes in liver disease.

HistoIndex's FibroSIGHT™ Plus: A Major Leap in Fibrosis Diagnosis Through AI Technology #Singapore #HistoIndex #FibroSIGHT_Plus #qFibrosis